How many 8-K filings has Vaccinex, Inc. filed?

Vaccinex, Inc. (VCNX) has 21 8-K (Current Event Report) filings on record, spanning Feb 2024 to Mar 2025.

What is a 8-K filing?

A 8-K is an SEC filing known as "Current Event Report." Filed to announce significant events or material changes such as acquisitions, executive departures, earnings announcements, or bankruptcy filings.

Where can I read Vaccinex, Inc. 8-K filings in plain English?

ReadTheFiling provides AI-powered plain-English summaries of all Vaccinex, Inc. 8-K filings, including risk assessment, sentiment analysis, and key financial figures.

Vaccinex, Inc. (VCNX) — 8-K Filings

All 8-K filings from Vaccinex, Inc.. Browse 21 Current Event Report reports with AI-powered summaries and risk analysis.

8-K Filings (21)

Vaccinex, Inc. Reports Director and Officer Changes — Mar 19, 2025 Risk: medium
Vaccinex, Inc. filed an 8-K on March 19, 2025, reporting changes effective March 18, 2025. The filing covers the departure and election of directors, appointmen
Vaccinex, Inc. Faces Listing Rule Concerns — Mar 7, 2025 Risk: high
On March 7, 2025, Vaccinex, Inc. filed an 8-K report indicating a potential delisting or failure to meet continued listing standards. The company, incorporated
Vaccinex, Inc. Faces Delisting Concerns — Dec 17, 2024 Risk: high
Vaccinex, Inc. filed an 8-K on December 17, 2024, reporting a notice of delisting or failure to satisfy continued listing rules, along with other events and fin
Vaccinex, Inc. Files 8-K on Material Agreement — Nov 14, 2024 Risk: medium
On November 13, 2024, Vaccinex, Inc. filed an 8-K report detailing a material definitive agreement. The filing also covers unregistered sales of equity securiti
Vaccinex Faces Delisting Concerns — Oct 9, 2024 Risk: high
Vaccinex, Inc. filed an 8-K on October 9, 2024, to report a notice of delisting or failure to satisfy a continued listing rule or standard. The company's common
Vaccinex, Inc. Files 8-K: Material Agreement & Equity Sales — Sep 19, 2024 Risk: medium
On September 17, 2024, Vaccinex, Inc. filed an 8-K report detailing a material definitive agreement. The filing also covers unregistered sales of equity securit
Vaccinex Appoints New CMO, Dr. Wagner Departs — Sep 13, 2024 Risk: medium
On September 10, 2024, Vaccinex, Inc. announced the departure of Dr. Christopher J. Wagner as Chief Medical Officer. The company also appointed Dr. Paul J. P. R
Vaccinex, Inc. Files 8-K Report — Aug 20, 2024 Risk: low
On August 20, 2024, Vaccinex, Inc. filed an 8-K report. The filing indicates that the company is involved in the pharmaceutical preparations industry, specifica
Vaccinex, Inc. Files 8-K Report — Aug 14, 2024 Risk: low
On August 14, 2024, Vaccinex, Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and the inclusion of Financial Statements and Exh
Vaccinex, Inc. Files 8-K Report — Jul 31, 2024 Risk: low
On July 31, 2024, Vaccinex, Inc. filed an 8-K report. The filing primarily concerns other events and financial statements/exhibits, with no specific material ev
Vaccinex, Inc. Files 8-K Report — Jun 6, 2024 Risk: low
On June 6, 2024, Vaccinex, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, indicating potential updates or disclosure
Vaccinex, Inc. Files 8-K on Shareholder Vote Matters — May 9, 2024 Risk: medium
On May 9, 2024, Vaccinex, Inc. filed an 8-K report detailing a submission of matters to a vote of security holders. The filing indicates that the company is see
Vaccinex Faces Delisting Concerns — Apr 12, 2024 Risk: high
Vaccinex, Inc. filed an 8-K on April 12, 2024, to report a notice of delisting or failure to satisfy a continued listing rule or standard. The company is based
Vaccinex, Inc. Files 8-K: Material Agreement, Equity Sales, Bylaw Changes — Apr 1, 2024 Risk: medium
On March 27, 2024, Vaccinex, Inc. entered into a material definitive agreement. The company also reported on unregistered sales of equity securities and amendme
Vaccinex, Inc. Files 8-K Report — Mar 28, 2024 Risk: low
On March 28, 2024, Vaccinex, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," indicating updates
Vaccinex, Inc. Files 8-K Report — Mar 27, 2024 Risk: low
On March 27, 2024, Vaccinex, Inc. filed an 8-K report. The filing indicates that the company is involved in the pharmaceutical preparations industry, with its p
Vaccinex, Inc. Reports Executive and Director Changes — Mar 4, 2024 Risk: medium
On February 27, 2024, Vaccinex, Inc. filed an 8-K report detailing changes in its executive and director positions. The filing indicates the departure of certai
Vaccinex Files 8-K for 'Other Events' and Financial Exhibits — Feb 21, 2024 Risk: low
Vaccinex, Inc. filed an 8-K on February 21, 2024, reporting an 'Other Event' and 'Financial Statements and Exhibits'. The filing indicates a current report purs
Vaccinex Files 8-K on Security Holder Rights, Bylaw Changes — Feb 15, 2024 Risk: medium
Vaccinex, Inc. filed an 8-K on February 15, 2024, reporting events that occurred on February 14, 2024. The filing indicates material modifications to the rights
Vaccinex Files 8-K for Shareholder Vote Submission — Feb 13, 2024 Risk: low
Vaccinex, Inc. filed an 8-K on February 13, 2024, to report an event that occurred on February 8, 2024. The filing, under Item 5.07, indicates the submission of
Vaccinex (VCNX) Reports Unregistered Equity Sales, Material Agreement — Feb 7, 2024
Vaccinex, Inc. (VCNX) filed an 8-K on February 7, 2024, reporting an "Entry into a Material Definitive Agreement" and "Unregistered Sales of Equity Securities"

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX